NEW YORK (GenomeWeb) – ArcherDx announced today that the New York State Department of Health (NYSDOH) has conditionally approved two of its FusionPlex assays for clinical use by Memorial Sloan Kettering Cancer Center.
The next-generation sequencing-based assays will be used to identify known and novel gene fusions in blood cancers, sarcomas, and solid tumors. They feature target enrichment by anchored multiplex PCR. MSKCC, which has performed studies and presented data on the RNA fusion panels, plans to use the assays alongside its MSK-Impact hybrid capture targeted DNA sequencing assay.
"Clinical utilization of AMP-based NGS RNA fusion assays has resulted in improved solid tumor, sarcoma, and hematological cancer diagnosis and treatment, and patient enrollment into clinical trials for therapies that target actionable gene fusions," ArcherDx said in a statement.
In June, the company signed a global co-marketing and distribution agreement with Illumina for its FusionPlex oncology products.